Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope
AssigneeImmunomedics, Inc.
InventorsShui-On Leung, Zhengxing Qu
Life of this patent
Estimating the term…
Abstract
Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using an antibody that binds with an epitope of an antigen that is associated with a tumor or an infectious agent, and that contains at least one α-galactosyl epitope. Such an antibody is capable of forming a complex with cells that express the target epitope and with antibodies that bind α-galactosyl epitopes. Suitable antibodies include molecules that contain at least one engineered glycosylation site in the constant region of the heavy chain.
Claims13
A method for stimulating humoral and cellular immune responses in a mammal against a tumor that expresses a tumor associated antigen (TAA) or against a disease caused by an infectious agent, said method comprising the step of:
- (a) administering an α-Gal antibody to the mammal, wherein said α-Gal antibody comprises:
- (i) an antibody component that binds with a specified target epitope, wherein said target epitope is an epitope of a TAA or an epitope of an antigen associated with an infectious agent, and
- (ii) at least one α-galactosyl epitope,
- wherein said α-Gal antibody can form a complex with cells that express said target epitope and antibodies that bind said α-galactosyl epitope.
A mutated antibody comprising:
- (a) a heavy chain having a constant region with an engineered glycosylation site, and
- (b) a carbohydrate moiety attached to said engineered glycosylation site, wherein said carbohydrate moiety comprises at least one α-galactosyl epitope.
A chimeric mLL2 antibody comprising:
- (a) a light chain variable region with a glycosylation site, and
- (b) a carbohydrate moiety attached to said engineered glycosylation site, wherein said carbohydrate moiety comprises at least one α-galactosyl epitope.
Dependencies are inferred from the claim text.